-- Two posters presented at the 14th Annual Meeting of the Oligonucleotide Therapeutics Society in Seattle, Washington --

-- Bio-distribution after oral delivery in mice shows efficacy of Exicure’s technology in a mouse model of inflammatory bowel disease --

-- Pre-clinical data presented by Regulus Therapeutics show Exicure’s technology improves exposure and targets gene modulation in the liver --

SKOKIE, Ill.--(BUSINESS WIRE)-- Exicure, Inc. (OTCQB: XCUR), the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional, spherical nucleic acid (SNA™) constructs, announced today that it has presented pre-clinical data in a poster session at the 14th Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) in Seattle, Washington from September 30-October 3, 2018.

“On behalf of the Exicure team, we are pleased to present the first data highlighting oral delivery of our spherical nucleic acid technology,” said Dr. David Giljohann, Chief Executive Officer of Exicure. “We are also sharing for the first time our work conducted with Regulus Therapeutics Inc. (NASDAQ: RGLS) showing that Exicure’s platform improves functional delivery of nucleic acids to the liver. Both studies underscore the importance of the Exicure technology for gene regulatory applications and open up new avenues for application of spherical nucleic acids.”

The first poster, authored and presented by Exicure scientists, titled “Spherical Nucleic Acids: Oral delivery and efficacy in TNBS-induced IBD model,” supports the local delivery benefits of Exicure’s proprietary platform technology. The imaging data presented in the poster show bio-distribution of SNAs following oral delivery in the GI tract of mice, including tissue penetration and cellular internalization. In addition, in a mouse model of inflammatory bowel disease, oral administration of SNAs showed improved clinical symptoms, colon gross pathology, body weight, and survival.

A second poster showcases data generated by Regulus Therapeutics through an ongoing scientific collaboration with Exicure. The poster, titled “Spherical Nucleic Acid (SNA) construct improves functional delivery of anti-microRNA oligonucleotide in pre-clinical studies in vitro and in vivo,” highlights improved delivery to the liver following systemic administration in mice and indicates the potential to broaden the application of Exicure’s proprietary SNA™ technology to miRNA targeting.

About Exicure, Inc.

Exicure, Inc. is a clinical stage biotechnology company developing a new class of immunomodulatory and gene regulating drugs against validated targets. Exicure's proprietary 3-dimensional, spherical nucleic acid spherical nucleic acid (SNA™) architecture is designed to unlock the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exicure's lead programs address inflammatory diseases, genetic disorders and oncology. Exicure is based outside of Chicago, IL. www.exicuretx.com.

Forward-Looking Statements

This press release contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning the Company, the Company’s technology, potential therapies and other matters. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “plan,” “believe,” “intend,” “look forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: unexpected costs, charges or expenses that reduce cash runway; that Exicure’s pre-clinical programs do not advance into the clinic or result in approved products on a timely or cost effective basis or at all; the cost, timing and results of pre-clinical and clinical trials; possible safety and efficacy concerns; regulatory developments; and the ability of Exicure to protect its intellectual property rights. Exicure’s pipeline programs are in various stages of pre-clinical and clinical development, and the process by which such pre-clinical or clinical therapeutic candidates could potentially lead to an approved therapeutic is long and subject to significant risks and uncertainties. Risks facing the Company and its programs are set forth in the Company’s filings with the SEC. Except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20181002005233/en/

MacDougall Biomedical Communications

Karen Sharma, 781-235-3060

[email protected]

or

The Del Mar Consulting Group, Inc.

Robert Prag, 858-794-9500

President

[email protected]

Source: Exicure, Inc.

Press Releases